In short
MPS-214 is one of the active substances in the investigational cancer vaccine OSE2101 (TEDOPI). This article examines ongoing clinical trials evaluating OSE2101, which contains MPS-214, for treating various types of cancer including non-small cell lung cancer, ovarian cancer, and pancreatic cancer. The trials aim to assess the safety and efficacy of OSE2101 alone or in combination with other therapies as a potential new treatment option for cancer patients.
What is MPS-214?
MPS-214 is one of the active substances in TEDOPI, an investigational cancer vaccine being developed by OSE Immunotherapeutics. It is a synthetically manufactured peptide, which is a small protein fragment. MPS-214 is part of a combination of 10 different peptides in TEDOPI designed to stimulate the immune system to fight cancer cells.
Role in TEDOPI Cancer Vaccine
TEDOPI is classified as a cancer vaccine, which means it is intended to help the body's immune system recognize and attack cancer cells. MPS-214, along with the other peptides in TEDOPI, is designed to target specific proteins found on cancer cells. By exposing the immune system to these peptides, the goal is to train it to identify and destroy cancer cells that express these proteins.
Conditions Treated
TEDOPI, which includes MPS-214, is being investigated for the treatment of several types of cancer:
- Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer, accounting for about 80-85% of all cases.
- Ovarian cancer: Specifically, platinum-sensitive recurrent ovarian cancer.
- Pancreatic cancer: Locally advanced or metastatic pancreatic ductal adenocarcinoma.
Clinical Trials
MPS-214, as part of TEDOPI, is currently being studied in several clinical trials:
- ARTEMIA study: A phase 3 trial comparing TEDOPI to docetaxel in patients with HLA-A2 positive metastatic non-small cell lung cancer who have developed resistance to immune checkpoint inhibitors.
- TEDOVA study: A phase 2 trial evaluating TEDOPI alone or in combination with pembrolizumab as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer.
- TEDOPAM study: A phase 2 trial assessing TEDOPI plus FOLFIRI chemotherapy as a maintenance treatment for patients with advanced pancreatic cancer after initial FOLFIRINOX treatment.
Administration
TEDOPI, containing MPS-214, is administered as an emulsion for injection. In clinical trials, it is typically given through subcutaneous injection, which means it is injected just under the skin. The exact dosing schedule may vary depending on the specific trial and condition being treated.
Potential Benefits
The potential benefits of TEDOPI, including MPS-214, are being evaluated in clinical trials. Researchers are looking at several outcomes, including:
- Overall survival (OS): How long patients live after starting treatment.
- Progression-free survival (PFS): How long patients live without their cancer getting worse.
- Objective response rate (ORR): The percentage of patients whose tumors shrink or disappear with treatment.
- Quality of life: How treatment affects patients' overall well-being and daily functioning.
Safety Considerations
As with any investigational treatment, the safety of TEDOPI (including MPS-214) is being closely monitored in clinical trials. Some important safety considerations include:
- TEDOPI is designed for patients with a specific genetic marker called HLA-A2. Patients must be tested for this marker before receiving the vaccine.
- Patients with certain autoimmune diseases or conditions that affect the immune system may not be eligible for treatment with TEDOPI.
- As TEDOPI stimulates the immune system, there is a potential for immune-related side effects. These are being carefully evaluated in the clinical trials.
- Women who are pregnant or breastfeeding are typically excluded from clinical trials of TEDOPI.
It's important to note that as an investigational treatment, the full safety profile of TEDOPI and MPS-214 is still being determined through ongoing clinical research.